|
MyHealthfinder Steering Committee
|
Committee, Work group, Advisory group, or Task Force
|
ODPHP, OASH, AHRQ, CDC, HRSA, FDA, CMS, SAMHSA
|
NLM, NCI, NIA
|
The MyHealthfinder Steering Committee comprises federal partners to help provide insight into the ways MyHealthfinder (an online health resource from HHS/ODPHP) more useful for public health professionals and the clients they serve. This group was formed in December 2020 and meets quarterly.
|
|
Nanotechnology Characterization Laboratory (NCL)
|
Research Initiative
|
FDA
|
NCI
|
The Nanotechnology Characterization Laboratory (NCL) performs and standardizes the preclinical characterization of nanomaterials intended for cancer therapeutics and diagnostics developed by researchers from academia, government, and industry. The NCL serves as a national resource and knowledge base for cancer researchers and facilitates the development and translation of nanoscale particles and devices for clinical applications.
|
|
NAPA Federal Subgroup
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, ASPE, ACL, CDC, CMS, FDA, HRSA, IHS
|
NIA, NINDS
|
This informal group of federal staff meets quarterly, in advance of the meetings of the Alzheimer’s Council for Alzheimer’s Research, Care, and Services, to exchange information on federal activities in the Alzheimer’s disease space and foster collaborations across agencies. From 2014-2021, NIA facilitated these meetings and set the focus on research opportunities; starting in 2022, HHS/ASPE will coordinate these meetings and promote discussion across all NAPA goals, including those related to research, care, supports, and risk reduction.
|
|
NASEM Aging Disability and Independence Forum
|
Committee, Work group, Advisory group, or Task Force
|
ACL
|
NIA
|
The National Academies of Sciences, Engineering, and Medicine have formed the Forum on Aging, Disability, and Independence to foster dialogue and address issues of mutual interest and concern related to aging and disability.
|
|
NASEM Forum on Drug Discovery, Development, and Translation
|
Committee, Work group, Advisory group, or Task Force
|
FDA, ASPR
|
NCATS, NINDS, NIAID, NCI, NIMH, OD/OSP
|
The Forum on Drug Discovery, Development, and Translation provides a neutral venue for stakeholders in government, academia, industry – including pharmaceutical, biotechnology, and digital health companies, foundations, and disease and patient advocacy to highlight critical issues, spur cross-sector collaboration, and inspire action towards improving the system of drug discovery, development, and translation. Forum-hosted public workshops, action collaboratives, and meetings focus on critical issues and practical approaches for advancing a clinical trials enterprise that is more efficient, effective, patient-centered, and integrated into the health delivery system.
|
|
NASEM Forum on Neuroscience and Nervous System Disorders
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NINDS, NCCIH, NIMH, NIAAA, NIA, NIEHS, NIDA
|
The National Academies of Sciences, Engineering, and Medicine's Forum on Neuroscience and Nervous System Disorders was established to bring together leaders from government, industry, academia, and disease advocacy organizations to examine issues concerning scientific needs and policies related to neuroscience and nervous system disorders research and the development and use of interventions for the nervous system. The Forum also sponsors workshops for its members and the public on key challenges and issues in the field.
|
|
NASEM Forum on Traumatic Brain Injury
|
Committee, Work group, Advisory group, or Task Force
|
ACL, CDC
|
NINDS, NICHD, NIA
|
The National Academies of Sciences, Engineering, and Medicine Forum on Traumatic Brain Injury provides a setting for experts to discuss how to advance the prevention, treatment, and care for people with brain injuries. The TBI Forum addresses topics relating to critical research gaps, TBI treatment and rehabilitation, and other related needs and challenges.
|
|
National Academy of Medicine Committee on Emerging Science, Technology, and Innovation in Health and Medicine
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIMH
|
The National Academy of Medicine has recently launched a new Committee on Emerging Science, Technology, and Innovation in health and medicine. The Committee will bring together experts in diverse fields to assess the landscape of emerging scientific advances and technologies in health and medicine and address the potential societal, ethical, legal, and workforce implications of such technologies. The goal of the Committee is to develop a multi-sectoral governance policy framework. The Committee plans to examine examples of emerging technologies and their implications for society, through a multi-sectoral lens. The first point of focus will be on neurotechnology, specifically transcranial direct current stimulation.
|
|
National Action Alliance for Suicide Prevention (NAASP)
|
Committee, Work group, Advisory group, or Task Force
|
ACL, CDC, HRSA, IHS, OS, Office of the Surgeon General (OSC), SAMHSA
|
NIMH, NIAAA, NIDA, OD/DPCPSI/OBSSR
|
Founded in September 2010, the National Action Alliance for Suicide Prevention (NAASP) is a public-private partnership designed to advance the National Strategy for Suicide Prevention in the United States. The NAASP's Research Prioritization Task Force (RPTF) was charged with developing a process to prioritize suicide prevention research efforts and consider ways to integrate science and service to ensure that suicide deaths decrease significantly within the next decade. The RPTF released the Nation's first suicide research agenda, A Prioritized Research Agenda for Suicide Prevention: An Action Plan to Save Lives. The research agenda includes an overarching goal to advance suicide prevention research more rapidly, seeking ways to reduce suicide deaths and attempts by 20 percent in five years and by 40 percent or greater in ten years. In 2015, the RPTF produced the "U.S. National Suicide Prevention Research Efforts: 2008-2013 Portfolio Analyses." The analyses revealed that investments in suicide research are severely lagging, but there is a growing knowledge base of intervention research. The National Institute of Mental Health (NIMH) Director serves as an ex-officio member of the Executive Committee of the NAASP. NIMH participates in a number of NAASP activities related to identifying research needs for improving risk identification and suicide preventive care within healthcare systems, justice, and school settings.
|
|
National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB) 2020-2025
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, BARDA, CDC, CMS, FDA, HRSA, OS
|
NIAID
|
The National Action Plan for Combating Antibiotic-resistant Bacteria, 2020-2025, was developed through the CARB Task Force, now reporting coordinated, strategic actions that the U.S. government takes to reduce the impact of antibiotic and antimicrobial resistance on the nation.
|